Risk classification of early-stage breast cancer patients by gene expression profiling can result in substantial drug cost savings. Economic analyses suggest that appropriate use of clinically validated molecular diagnostics offers the potential for cost savings and improved patient quality of life.

Original languageEnglish
Pages (from-to)9-12; discussion 17-18
JournalManaged care (Langhorne, Pa.)
Issue number7 Suppl 7
StatePublished - Jul 2008

ASJC Scopus subject areas

  • Health Policy
  • Public Health, Environmental and Occupational Health


Dive into the research topics of 'Assessing therapeutically developed assays.'. Together they form a unique fingerprint.

Cite this